Medacta Group S.A. (MOVE.SW) stock: Winston Score, insiders and Congress trades

Medacta Group is a Swiss medical device company that makes artificial joints and surgical tools used in hospitals around the world. Its main products are replacement implants for knees, hips, shoulders, and spines — the kind surgeons use when a patient's natural joint wears out or gets damaged. Medacta also sells a surgical training system called MyKnee and MyShoulder, which uses patient scans to help surgeons plan and perform more precise operations. The company earns money by selling its implants and related instruments directly to hospitals and surgical centers, mostly through its own sales force rather than third-party distributors. Medacta operates primarily in Europe, the United States, and Australia, with the U.S. market being a key growth target. Its main competitive edge comes from its surgeon education programs and proprietary surgical techniques, which create loyalty among doctors who train on its systems. The biggest risk is competing against much larger rivals like Zimmer Biomet and Stryker, which have far greater resources and established hospital relationships.

Editorial rules set and reviewed by Felix Prehn, Economist and Editor. Figures are refreshed daily from Financial Modeling Prep and company filings; last refreshed 2026-10-08.